Global Peptide and Oligonucleotide CDMO Market Growth (Status and Outlook) 2026-2032
The global Peptide and Oligonucleotide CDMO market size is predicted to grow from US$ 2046 million in 2025 to US$ 4031 million in 2032; it is expected to grow at a CAGR of 10.4% from 2026 to 2032.
United States market for Peptide and Oligonucleotide CDMO is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Peptide and Oligonucleotide CDMO is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Peptide and Oligonucleotide CDMO is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Peptide and Oligonucleotide CDMO players cover Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Catalent, Inc., Genscript Biotech Corporation, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Peptide and Oligonucleotide CDMO Industry Forecast” looks at past sales and reviews total world Peptide and Oligonucleotide CDMO sales in 2025, providing a comprehensive analysis by region and market sector of projected Peptide and Oligonucleotide CDMO sales for 2026 through 2032. With Peptide and Oligonucleotide CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide and Oligonucleotide CDMO industry.
This Insight Report provides a comprehensive analysis of the global Peptide and Oligonucleotide CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Peptide and Oligonucleotide CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Peptide and Oligonucleotide CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide and Oligonucleotide CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide and Oligonucleotide CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide and Oligonucleotide CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
United States market for Peptide and Oligonucleotide CDMO is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Peptide and Oligonucleotide CDMO is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Peptide and Oligonucleotide CDMO is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Peptide and Oligonucleotide CDMO players cover Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Catalent, Inc., Genscript Biotech Corporation, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Peptide and Oligonucleotide CDMO Industry Forecast” looks at past sales and reviews total world Peptide and Oligonucleotide CDMO sales in 2025, providing a comprehensive analysis by region and market sector of projected Peptide and Oligonucleotide CDMO sales for 2026 through 2032. With Peptide and Oligonucleotide CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide and Oligonucleotide CDMO industry.
This Insight Report provides a comprehensive analysis of the global Peptide and Oligonucleotide CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Peptide and Oligonucleotide CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Peptide and Oligonucleotide CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide and Oligonucleotide CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide and Oligonucleotide CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide and Oligonucleotide CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Peptide CDMO
- Oligonucleotide CDMO
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Lonza Group Ltd.
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Catalent, Inc.
- Genscript Biotech Corporation
- Polypeptide Group
- Bachem Holding AG
- Wuxi Apptec Co., Ltd.
- Ajinomoto Co., Inc.
- Rentschler Biopharma SE
- Corden Pharma GmbH
- Senn Chemicals AG
- Almac Group
- Lonza Custom Manufacturing
- Creative Peptides
- Swiss Customized Synthesis
- Syngene
- Eurogentec
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Peptide and Oligonucleotide CDMO Market Size (2021-2032)
2.1.2 Peptide and Oligonucleotide CDMO Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Peptide and Oligonucleotide CDMO by Country/Region (2021, 2025 & 2032)
2.2 Peptide and Oligonucleotide CDMO Segment by Type
2.2.1 Peptide CDMO
2.2.2 Oligonucleotide CDMO
2.2.3 Peptide and Oligonucleotide CDMO Market Size by Type
2.2.3.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2021-2026)
2.3 Peptide and Oligonucleotide CDMO Segment by Application
2.3.1 Pharmaceutical and Biotechnology Companies
2.3.2 Research Institutes
2.3.3 Others
2.3.4 Peptide and Oligonucleotide CDMO Market Size by Application
2.3.4.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2021-2026)
3 PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET SIZE BY PLAYER
3.1 Peptide and Oligonucleotide CDMO Market Size Market Share by Player
3.1.1 Global Peptide and Oligonucleotide CDMO Revenue by Player (2021-2026)
3.1.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Player (2021-2026)
3.2 Global Peptide and Oligonucleotide CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PEPTIDE AND OLIGONUCLEOTIDE CDMO BY REGION
4.1 Peptide and Oligonucleotide CDMO Market Size by Region (2021-2026)
4.2 Global Peptide and Oligonucleotide CDMO Annual Revenue by Country/Region (2021-2026)
4.3 Americas Peptide and Oligonucleotide CDMO Market Size Growth (2021-2026)
4.4 APAC Peptide and Oligonucleotide CDMO Market Size Growth (2021-2026)
4.5 Europe Peptide and Oligonucleotide CDMO Market Size Growth (2021-2026)
4.6 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Peptide and Oligonucleotide CDMO Market Size by Country (2021-2026)
5.2 Americas Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026)
5.3 Americas Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide and Oligonucleotide CDMO Market Size by Region (2021-2026)
6.2 APAC Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026)
6.3 APAC Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Peptide and Oligonucleotide CDMO Market Size by Country (2021-2026)
7.2 Europe Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026)
7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Peptide and Oligonucleotide CDMO by Region (2021-2026)
8.2 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026)
8.3 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET FORECAST
10.1 Global Peptide and Oligonucleotide CDMO Forecast by Region (2027-2032)
10.1.1 Global Peptide and Oligonucleotide CDMO Forecast by Region (2027-2032)
10.1.2 Americas Peptide and Oligonucleotide CDMO Forecast
10.1.3 APAC Peptide and Oligonucleotide CDMO Forecast
10.1.4 Europe Peptide and Oligonucleotide CDMO Forecast
10.1.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast
10.2 Americas Peptide and Oligonucleotide CDMO Forecast by Country (2027-2032)
10.2.1 United States Market Peptide and Oligonucleotide CDMO Forecast
10.2.2 Canada Market Peptide and Oligonucleotide CDMO Forecast
10.2.3 Mexico Market Peptide and Oligonucleotide CDMO Forecast
10.2.4 Brazil Market Peptide and Oligonucleotide CDMO Forecast
10.3 APAC Peptide and Oligonucleotide CDMO Forecast by Region (2027-2032)
10.3.1 China Peptide and Oligonucleotide CDMO Market Forecast
10.3.2 Japan Market Peptide and Oligonucleotide CDMO Forecast
10.3.3 Korea Market Peptide and Oligonucleotide CDMO Forecast
10.3.4 Southeast Asia Market Peptide and Oligonucleotide CDMO Forecast
10.3.5 India Market Peptide and Oligonucleotide CDMO Forecast
10.3.6 Australia Market Peptide and Oligonucleotide CDMO Forecast
10.4 Europe Peptide and Oligonucleotide CDMO Forecast by Country (2027-2032)
10.4.1 Germany Market Peptide and Oligonucleotide CDMO Forecast
10.4.2 France Market Peptide and Oligonucleotide CDMO Forecast
10.4.3 UK Market Peptide and Oligonucleotide CDMO Forecast
10.4.4 Italy Market Peptide and Oligonucleotide CDMO Forecast
10.4.5 Russia Market Peptide and Oligonucleotide CDMO Forecast
10.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast by Region (2027-2032)
10.5.1 Egypt Market Peptide and Oligonucleotide CDMO Forecast
10.5.2 South Africa Market Peptide and Oligonucleotide CDMO Forecast
10.5.3 Israel Market Peptide and Oligonucleotide CDMO Forecast
10.5.4 Turkey Market Peptide and Oligonucleotide CDMO Forecast
10.6 Global Peptide and Oligonucleotide CDMO Forecast by Type (2027-2032)
10.7 Global Peptide and Oligonucleotide CDMO Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Peptide and Oligonucleotide CDMO Forecast
11 KEY PLAYERS ANALYSIS
11.1 Lonza Group Ltd.
11.1.1 Lonza Group Ltd. Company Information
11.1.2 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Offered
11.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Lonza Group Ltd. Main Business Overview
11.1.5 Lonza Group Ltd. Latest Developments
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Information
11.2.2 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Offered
11.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Thermo Fisher Scientific Inc. Main Business Overview
11.2.5 Thermo Fisher Scientific Inc. Latest Developments
11.3 Merck KGaA
11.3.1 Merck KGaA Company Information
11.3.2 Merck KGaA Peptide and Oligonucleotide CDMO Product Offered
11.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Merck KGaA Main Business Overview
11.3.5 Merck KGaA Latest Developments
11.4 Catalent, Inc.
11.4.1 Catalent, Inc. Company Information
11.4.2 Catalent, Inc. Peptide and Oligonucleotide CDMO Product Offered
11.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Catalent, Inc. Main Business Overview
11.4.5 Catalent, Inc. Latest Developments
11.5 Genscript Biotech Corporation
11.5.1 Genscript Biotech Corporation Company Information
11.5.2 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Offered
11.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Genscript Biotech Corporation Main Business Overview
11.5.5 Genscript Biotech Corporation Latest Developments
11.6 Polypeptide Group
11.6.1 Polypeptide Group Company Information
11.6.2 Polypeptide Group Peptide and Oligonucleotide CDMO Product Offered
11.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Polypeptide Group Main Business Overview
11.6.5 Polypeptide Group Latest Developments
11.7 Bachem Holding AG
11.7.1 Bachem Holding AG Company Information
11.7.2 Bachem Holding AG Peptide and Oligonucleotide CDMO Product Offered
11.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Bachem Holding AG Main Business Overview
11.7.5 Bachem Holding AG Latest Developments
11.8 Wuxi Apptec Co., Ltd.
11.8.1 Wuxi Apptec Co., Ltd. Company Information
11.8.2 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Offered
11.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Wuxi Apptec Co., Ltd. Main Business Overview
11.8.5 Wuxi Apptec Co., Ltd. Latest Developments
11.9 Ajinomoto Co., Inc.
11.9.1 Ajinomoto Co., Inc. Company Information
11.9.2 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Offered
11.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Ajinomoto Co., Inc. Main Business Overview
11.9.5 Ajinomoto Co., Inc. Latest Developments
11.10 Rentschler Biopharma SE
11.10.1 Rentschler Biopharma SE Company Information
11.10.2 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Offered
11.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Rentschler Biopharma SE Main Business Overview
11.10.5 Rentschler Biopharma SE Latest Developments
11.11 Corden Pharma GmbH
11.11.1 Corden Pharma GmbH Company Information
11.11.2 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Offered
11.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Corden Pharma GmbH Main Business Overview
11.11.5 Corden Pharma GmbH Latest Developments
11.12 Senn Chemicals AG
11.12.1 Senn Chemicals AG Company Information
11.12.2 Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Offered
11.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Senn Chemicals AG Main Business Overview
11.12.5 Senn Chemicals AG Latest Developments
11.13 Almac Group
11.13.1 Almac Group Company Information
11.13.2 Almac Group Peptide and Oligonucleotide CDMO Product Offered
11.13.3 Almac Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Almac Group Main Business Overview
11.13.5 Almac Group Latest Developments
11.14 Lonza Custom Manufacturing
11.14.1 Lonza Custom Manufacturing Company Information
11.14.2 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Offered
11.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Lonza Custom Manufacturing Main Business Overview
11.14.5 Lonza Custom Manufacturing Latest Developments
11.15 Creative Peptides
11.15.1 Creative Peptides Company Information
11.15.2 Creative Peptides Peptide and Oligonucleotide CDMO Product Offered
11.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Creative Peptides Main Business Overview
11.15.5 Creative Peptides Latest Developments
11.16 Swiss Customized Synthesis
11.16.1 Swiss Customized Synthesis Company Information
11.16.2 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Offered
11.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Swiss Customized Synthesis Main Business Overview
11.16.5 Swiss Customized Synthesis Latest Developments
11.17 Syngene
11.17.1 Syngene Company Information
11.17.2 Syngene Peptide and Oligonucleotide CDMO Product Offered
11.17.3 Syngene Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Syngene Main Business Overview
11.17.5 Syngene Latest Developments
11.18 Eurogentec
11.18.1 Eurogentec Company Information
11.18.2 Eurogentec Peptide and Oligonucleotide CDMO Product Offered
11.18.3 Eurogentec Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Eurogentec Main Business Overview
11.18.5 Eurogentec Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Peptide and Oligonucleotide CDMO Market Size (2021-2032)
2.1.2 Peptide and Oligonucleotide CDMO Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Peptide and Oligonucleotide CDMO by Country/Region (2021, 2025 & 2032)
2.2 Peptide and Oligonucleotide CDMO Segment by Type
2.2.1 Peptide CDMO
2.2.2 Oligonucleotide CDMO
2.2.3 Peptide and Oligonucleotide CDMO Market Size by Type
2.2.3.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2021-2026)
2.3 Peptide and Oligonucleotide CDMO Segment by Application
2.3.1 Pharmaceutical and Biotechnology Companies
2.3.2 Research Institutes
2.3.3 Others
2.3.4 Peptide and Oligonucleotide CDMO Market Size by Application
2.3.4.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2021-2026)
3 PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET SIZE BY PLAYER
3.1 Peptide and Oligonucleotide CDMO Market Size Market Share by Player
3.1.1 Global Peptide and Oligonucleotide CDMO Revenue by Player (2021-2026)
3.1.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Player (2021-2026)
3.2 Global Peptide and Oligonucleotide CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PEPTIDE AND OLIGONUCLEOTIDE CDMO BY REGION
4.1 Peptide and Oligonucleotide CDMO Market Size by Region (2021-2026)
4.2 Global Peptide and Oligonucleotide CDMO Annual Revenue by Country/Region (2021-2026)
4.3 Americas Peptide and Oligonucleotide CDMO Market Size Growth (2021-2026)
4.4 APAC Peptide and Oligonucleotide CDMO Market Size Growth (2021-2026)
4.5 Europe Peptide and Oligonucleotide CDMO Market Size Growth (2021-2026)
4.6 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Peptide and Oligonucleotide CDMO Market Size by Country (2021-2026)
5.2 Americas Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026)
5.3 Americas Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide and Oligonucleotide CDMO Market Size by Region (2021-2026)
6.2 APAC Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026)
6.3 APAC Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Peptide and Oligonucleotide CDMO Market Size by Country (2021-2026)
7.2 Europe Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026)
7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Peptide and Oligonucleotide CDMO by Region (2021-2026)
8.2 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026)
8.3 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET FORECAST
10.1 Global Peptide and Oligonucleotide CDMO Forecast by Region (2027-2032)
10.1.1 Global Peptide and Oligonucleotide CDMO Forecast by Region (2027-2032)
10.1.2 Americas Peptide and Oligonucleotide CDMO Forecast
10.1.3 APAC Peptide and Oligonucleotide CDMO Forecast
10.1.4 Europe Peptide and Oligonucleotide CDMO Forecast
10.1.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast
10.2 Americas Peptide and Oligonucleotide CDMO Forecast by Country (2027-2032)
10.2.1 United States Market Peptide and Oligonucleotide CDMO Forecast
10.2.2 Canada Market Peptide and Oligonucleotide CDMO Forecast
10.2.3 Mexico Market Peptide and Oligonucleotide CDMO Forecast
10.2.4 Brazil Market Peptide and Oligonucleotide CDMO Forecast
10.3 APAC Peptide and Oligonucleotide CDMO Forecast by Region (2027-2032)
10.3.1 China Peptide and Oligonucleotide CDMO Market Forecast
10.3.2 Japan Market Peptide and Oligonucleotide CDMO Forecast
10.3.3 Korea Market Peptide and Oligonucleotide CDMO Forecast
10.3.4 Southeast Asia Market Peptide and Oligonucleotide CDMO Forecast
10.3.5 India Market Peptide and Oligonucleotide CDMO Forecast
10.3.6 Australia Market Peptide and Oligonucleotide CDMO Forecast
10.4 Europe Peptide and Oligonucleotide CDMO Forecast by Country (2027-2032)
10.4.1 Germany Market Peptide and Oligonucleotide CDMO Forecast
10.4.2 France Market Peptide and Oligonucleotide CDMO Forecast
10.4.3 UK Market Peptide and Oligonucleotide CDMO Forecast
10.4.4 Italy Market Peptide and Oligonucleotide CDMO Forecast
10.4.5 Russia Market Peptide and Oligonucleotide CDMO Forecast
10.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast by Region (2027-2032)
10.5.1 Egypt Market Peptide and Oligonucleotide CDMO Forecast
10.5.2 South Africa Market Peptide and Oligonucleotide CDMO Forecast
10.5.3 Israel Market Peptide and Oligonucleotide CDMO Forecast
10.5.4 Turkey Market Peptide and Oligonucleotide CDMO Forecast
10.6 Global Peptide and Oligonucleotide CDMO Forecast by Type (2027-2032)
10.7 Global Peptide and Oligonucleotide CDMO Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Peptide and Oligonucleotide CDMO Forecast
11 KEY PLAYERS ANALYSIS
11.1 Lonza Group Ltd.
11.1.1 Lonza Group Ltd. Company Information
11.1.2 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Offered
11.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Lonza Group Ltd. Main Business Overview
11.1.5 Lonza Group Ltd. Latest Developments
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Information
11.2.2 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Offered
11.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Thermo Fisher Scientific Inc. Main Business Overview
11.2.5 Thermo Fisher Scientific Inc. Latest Developments
11.3 Merck KGaA
11.3.1 Merck KGaA Company Information
11.3.2 Merck KGaA Peptide and Oligonucleotide CDMO Product Offered
11.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Merck KGaA Main Business Overview
11.3.5 Merck KGaA Latest Developments
11.4 Catalent, Inc.
11.4.1 Catalent, Inc. Company Information
11.4.2 Catalent, Inc. Peptide and Oligonucleotide CDMO Product Offered
11.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Catalent, Inc. Main Business Overview
11.4.5 Catalent, Inc. Latest Developments
11.5 Genscript Biotech Corporation
11.5.1 Genscript Biotech Corporation Company Information
11.5.2 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Offered
11.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Genscript Biotech Corporation Main Business Overview
11.5.5 Genscript Biotech Corporation Latest Developments
11.6 Polypeptide Group
11.6.1 Polypeptide Group Company Information
11.6.2 Polypeptide Group Peptide and Oligonucleotide CDMO Product Offered
11.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Polypeptide Group Main Business Overview
11.6.5 Polypeptide Group Latest Developments
11.7 Bachem Holding AG
11.7.1 Bachem Holding AG Company Information
11.7.2 Bachem Holding AG Peptide and Oligonucleotide CDMO Product Offered
11.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Bachem Holding AG Main Business Overview
11.7.5 Bachem Holding AG Latest Developments
11.8 Wuxi Apptec Co., Ltd.
11.8.1 Wuxi Apptec Co., Ltd. Company Information
11.8.2 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Offered
11.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Wuxi Apptec Co., Ltd. Main Business Overview
11.8.5 Wuxi Apptec Co., Ltd. Latest Developments
11.9 Ajinomoto Co., Inc.
11.9.1 Ajinomoto Co., Inc. Company Information
11.9.2 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Offered
11.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Ajinomoto Co., Inc. Main Business Overview
11.9.5 Ajinomoto Co., Inc. Latest Developments
11.10 Rentschler Biopharma SE
11.10.1 Rentschler Biopharma SE Company Information
11.10.2 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Offered
11.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Rentschler Biopharma SE Main Business Overview
11.10.5 Rentschler Biopharma SE Latest Developments
11.11 Corden Pharma GmbH
11.11.1 Corden Pharma GmbH Company Information
11.11.2 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Offered
11.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Corden Pharma GmbH Main Business Overview
11.11.5 Corden Pharma GmbH Latest Developments
11.12 Senn Chemicals AG
11.12.1 Senn Chemicals AG Company Information
11.12.2 Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Offered
11.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Senn Chemicals AG Main Business Overview
11.12.5 Senn Chemicals AG Latest Developments
11.13 Almac Group
11.13.1 Almac Group Company Information
11.13.2 Almac Group Peptide and Oligonucleotide CDMO Product Offered
11.13.3 Almac Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Almac Group Main Business Overview
11.13.5 Almac Group Latest Developments
11.14 Lonza Custom Manufacturing
11.14.1 Lonza Custom Manufacturing Company Information
11.14.2 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Offered
11.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Lonza Custom Manufacturing Main Business Overview
11.14.5 Lonza Custom Manufacturing Latest Developments
11.15 Creative Peptides
11.15.1 Creative Peptides Company Information
11.15.2 Creative Peptides Peptide and Oligonucleotide CDMO Product Offered
11.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Creative Peptides Main Business Overview
11.15.5 Creative Peptides Latest Developments
11.16 Swiss Customized Synthesis
11.16.1 Swiss Customized Synthesis Company Information
11.16.2 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Offered
11.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Swiss Customized Synthesis Main Business Overview
11.16.5 Swiss Customized Synthesis Latest Developments
11.17 Syngene
11.17.1 Syngene Company Information
11.17.2 Syngene Peptide and Oligonucleotide CDMO Product Offered
11.17.3 Syngene Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Syngene Main Business Overview
11.17.5 Syngene Latest Developments
11.18 Eurogentec
11.18.1 Eurogentec Company Information
11.18.2 Eurogentec Peptide and Oligonucleotide CDMO Product Offered
11.18.3 Eurogentec Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Eurogentec Main Business Overview
11.18.5 Eurogentec Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Peptide and Oligonucleotide CDMO Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Peptide and Oligonucleotide CDMO Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Peptide CDMO
Table 4. Major Players of Oligonucleotide CDMO
Table 5. Peptide and Oligonucleotide CDMO Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2021-2026)
Table 8. Peptide and Oligonucleotide CDMO Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2021-2026)
Table 11. Global Peptide and Oligonucleotide CDMO Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Player (2021-2026)
Table 13. Peptide and Oligonucleotide CDMO Key Players Head office and Products Offered
Table 14. Peptide and Oligonucleotide CDMO Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Peptide and Oligonucleotide CDMO Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Region (2021-2026)
Table 19. Global Peptide and Oligonucleotide CDMO Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Peptide and Oligonucleotide CDMO Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Peptide and Oligonucleotide CDMO Market Size Market Share by Country (2021-2026)
Table 23. Americas Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2021-2026)
Table 25. Americas Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2021-2026)
Table 27. APAC Peptide and Oligonucleotide CDMO Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Region (2021-2026)
Table 29. APAC Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Peptide and Oligonucleotide CDMO Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Country (2021-2026)
Table 33. Europe Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Peptide and Oligonucleotide CDMO
Table 39. Key Market Challenges & Risks of Peptide and Oligonucleotide CDMO
Table 40. Key Industry Trends of Peptide and Oligonucleotide CDMO
Table 41. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Peptide and Oligonucleotide CDMO Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Lonza Group Ltd. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 46. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Offered
Table 47. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Lonza Group Ltd. Main Business
Table 49. Lonza Group Ltd. Latest Developments
Table 50. Thermo Fisher Scientific Inc. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 51. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Offered
Table 52. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Thermo Fisher Scientific Inc. Main Business
Table 54. Thermo Fisher Scientific Inc. Latest Developments
Table 55. Merck KGaA Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 56. Merck KGaA Peptide and Oligonucleotide CDMO Product Offered
Table 57. Merck KGaA Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Merck KGaA Main Business
Table 59. Merck KGaA Latest Developments
Table 60. Catalent, Inc. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 61. Catalent, Inc. Peptide and Oligonucleotide CDMO Product Offered
Table 62. Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Catalent, Inc. Main Business
Table 64. Catalent, Inc. Latest Developments
Table 65. Genscript Biotech Corporation Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 66. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Offered
Table 67. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Genscript Biotech Corporation Main Business
Table 69. Genscript Biotech Corporation Latest Developments
Table 70. Polypeptide Group Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 71. Polypeptide Group Peptide and Oligonucleotide CDMO Product Offered
Table 72. Polypeptide Group Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Polypeptide Group Main Business
Table 74. Polypeptide Group Latest Developments
Table 75. Bachem Holding AG Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 76. Bachem Holding AG Peptide and Oligonucleotide CDMO Product Offered
Table 77. Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Bachem Holding AG Main Business
Table 79. Bachem Holding AG Latest Developments
Table 80. Wuxi Apptec Co., Ltd. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 81. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Offered
Table 82. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Wuxi Apptec Co., Ltd. Main Business
Table 84. Wuxi Apptec Co., Ltd. Latest Developments
Table 85. Ajinomoto Co., Inc. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 86. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Offered
Table 87. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Ajinomoto Co., Inc. Main Business
Table 89. Ajinomoto Co., Inc. Latest Developments
Table 90. Rentschler Biopharma SE Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 91. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Offered
Table 92. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Rentschler Biopharma SE Main Business
Table 94. Rentschler Biopharma SE Latest Developments
Table 95. Corden Pharma GmbH Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 96. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Offered
Table 97. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Corden Pharma GmbH Main Business
Table 99. Corden Pharma GmbH Latest Developments
Table 100. Senn Chemicals AG Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 101. Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Offered
Table 102. Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Senn Chemicals AG Main Business
Table 104. Senn Chemicals AG Latest Developments
Table 105. Almac Group Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 106. Almac Group Peptide and Oligonucleotide CDMO Product Offered
Table 107. Almac Group Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Almac Group Main Business
Table 109. Almac Group Latest Developments
Table 110. Lonza Custom Manufacturing Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 111. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Offered
Table 112. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Lonza Custom Manufacturing Main Business
Table 114. Lonza Custom Manufacturing Latest Developments
Table 115. Creative Peptides Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 116. Creative Peptides Peptide and Oligonucleotide CDMO Product Offered
Table 117. Creative Peptides Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Creative Peptides Main Business
Table 119. Creative Peptides Latest Developments
Table 120. Swiss Customized Synthesis Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 121. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Offered
Table 122. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. Swiss Customized Synthesis Main Business
Table 124. Swiss Customized Synthesis Latest Developments
Table 125. Syngene Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 126. Syngene Peptide and Oligonucleotide CDMO Product Offered
Table 127. Syngene Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Syngene Main Business
Table 129. Syngene Latest Developments
Table 130. Eurogentec Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 131. Eurogentec Peptide and Oligonucleotide CDMO Product Offered
Table 132. Eurogentec Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 133. Eurogentec Main Business
Table 134. Eurogentec Latest Developments
Table 1. Peptide and Oligonucleotide CDMO Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Peptide and Oligonucleotide CDMO Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Peptide CDMO
Table 4. Major Players of Oligonucleotide CDMO
Table 5. Peptide and Oligonucleotide CDMO Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2021-2026)
Table 8. Peptide and Oligonucleotide CDMO Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2021-2026)
Table 11. Global Peptide and Oligonucleotide CDMO Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Player (2021-2026)
Table 13. Peptide and Oligonucleotide CDMO Key Players Head office and Products Offered
Table 14. Peptide and Oligonucleotide CDMO Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Peptide and Oligonucleotide CDMO Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Region (2021-2026)
Table 19. Global Peptide and Oligonucleotide CDMO Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Peptide and Oligonucleotide CDMO Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Peptide and Oligonucleotide CDMO Market Size Market Share by Country (2021-2026)
Table 23. Americas Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2021-2026)
Table 25. Americas Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2021-2026)
Table 27. APAC Peptide and Oligonucleotide CDMO Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Region (2021-2026)
Table 29. APAC Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Peptide and Oligonucleotide CDMO Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Country (2021-2026)
Table 33. Europe Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Peptide and Oligonucleotide CDMO
Table 39. Key Market Challenges & Risks of Peptide and Oligonucleotide CDMO
Table 40. Key Industry Trends of Peptide and Oligonucleotide CDMO
Table 41. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Peptide and Oligonucleotide CDMO Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Lonza Group Ltd. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 46. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Offered
Table 47. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Lonza Group Ltd. Main Business
Table 49. Lonza Group Ltd. Latest Developments
Table 50. Thermo Fisher Scientific Inc. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 51. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Offered
Table 52. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Thermo Fisher Scientific Inc. Main Business
Table 54. Thermo Fisher Scientific Inc. Latest Developments
Table 55. Merck KGaA Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 56. Merck KGaA Peptide and Oligonucleotide CDMO Product Offered
Table 57. Merck KGaA Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Merck KGaA Main Business
Table 59. Merck KGaA Latest Developments
Table 60. Catalent, Inc. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 61. Catalent, Inc. Peptide and Oligonucleotide CDMO Product Offered
Table 62. Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Catalent, Inc. Main Business
Table 64. Catalent, Inc. Latest Developments
Table 65. Genscript Biotech Corporation Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 66. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Offered
Table 67. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Genscript Biotech Corporation Main Business
Table 69. Genscript Biotech Corporation Latest Developments
Table 70. Polypeptide Group Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 71. Polypeptide Group Peptide and Oligonucleotide CDMO Product Offered
Table 72. Polypeptide Group Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Polypeptide Group Main Business
Table 74. Polypeptide Group Latest Developments
Table 75. Bachem Holding AG Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 76. Bachem Holding AG Peptide and Oligonucleotide CDMO Product Offered
Table 77. Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Bachem Holding AG Main Business
Table 79. Bachem Holding AG Latest Developments
Table 80. Wuxi Apptec Co., Ltd. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 81. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Offered
Table 82. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Wuxi Apptec Co., Ltd. Main Business
Table 84. Wuxi Apptec Co., Ltd. Latest Developments
Table 85. Ajinomoto Co., Inc. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 86. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Offered
Table 87. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Ajinomoto Co., Inc. Main Business
Table 89. Ajinomoto Co., Inc. Latest Developments
Table 90. Rentschler Biopharma SE Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 91. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Offered
Table 92. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Rentschler Biopharma SE Main Business
Table 94. Rentschler Biopharma SE Latest Developments
Table 95. Corden Pharma GmbH Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 96. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Offered
Table 97. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Corden Pharma GmbH Main Business
Table 99. Corden Pharma GmbH Latest Developments
Table 100. Senn Chemicals AG Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 101. Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Offered
Table 102. Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Senn Chemicals AG Main Business
Table 104. Senn Chemicals AG Latest Developments
Table 105. Almac Group Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 106. Almac Group Peptide and Oligonucleotide CDMO Product Offered
Table 107. Almac Group Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Almac Group Main Business
Table 109. Almac Group Latest Developments
Table 110. Lonza Custom Manufacturing Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 111. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Offered
Table 112. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Lonza Custom Manufacturing Main Business
Table 114. Lonza Custom Manufacturing Latest Developments
Table 115. Creative Peptides Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 116. Creative Peptides Peptide and Oligonucleotide CDMO Product Offered
Table 117. Creative Peptides Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Creative Peptides Main Business
Table 119. Creative Peptides Latest Developments
Table 120. Swiss Customized Synthesis Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 121. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Offered
Table 122. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. Swiss Customized Synthesis Main Business
Table 124. Swiss Customized Synthesis Latest Developments
Table 125. Syngene Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 126. Syngene Peptide and Oligonucleotide CDMO Product Offered
Table 127. Syngene Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Syngene Main Business
Table 129. Syngene Latest Developments
Table 130. Eurogentec Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 131. Eurogentec Peptide and Oligonucleotide CDMO Product Offered
Table 132. Eurogentec Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 133. Eurogentec Main Business
Table 134. Eurogentec Latest Developments
LIST OF FIGURES
Figure 1. Peptide and Oligonucleotide CDMO Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Peptide and Oligonucleotide CDMO Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Peptide and Oligonucleotide CDMO Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Peptide and Oligonucleotide CDMO Sales Market Share by Country/Region (2025)
Figure 8. Peptide and Oligonucleotide CDMO Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type in 2025
Figure 10. Peptide and Oligonucleotide CDMO in Pharmaceutical and Biotechnology Companies
Figure 11. Global Peptide and Oligonucleotide CDMO Market: Pharmaceutical and Biotechnology Companies (2021-2026) & ($ millions)
Figure 12. Peptide and Oligonucleotide CDMO in Research Institutes
Figure 13. Global Peptide and Oligonucleotide CDMO Market: Research Institutes (2021-2026) & ($ millions)
Figure 14. Peptide and Oligonucleotide CDMO in Others
Figure 15. Global Peptide and Oligonucleotide CDMO Market: Others (2021-2026) & ($ millions)
Figure 16. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application in 2025
Figure 17. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Player in 2025
Figure 18. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Region (2021-2026)
Figure 19. Americas Peptide and Oligonucleotide CDMO Market Size 2021-2026 ($ millions)
Figure 20. APAC Peptide and Oligonucleotide CDMO Market Size 2021-2026 ($ millions)
Figure 21. Europe Peptide and Oligonucleotide CDMO Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size 2021-2026 ($ millions)
Figure 23. Americas Peptide and Oligonucleotide CDMO Value Market Share by Country in 2025
Figure 24. United States Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Region in 2025
Figure 29. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2021-2026)
Figure 30. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2021-2026)
Figure 31. China Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 35. India Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Country in 2025
Figure 38. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2021-2026)
Figure 39. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2021-2026)
Figure 40. Germany Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 41. France Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 54. APAC Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 55. Europe Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 57. United States Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 58. Canada Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 59. Mexico Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 60. Brazil Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 61. China Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 62. Japan Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 63. Korea Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 65. India Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 66. Australia Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 67. Germany Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 68. France Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 69. UK Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 70. Italy Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 71. Russia Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 72. Egypt Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 73. South Africa Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 74. Israel Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 75. Turkey Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 76. Global Peptide and Oligonucleotide CDMO Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Peptide and Oligonucleotide CDMO Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 1. Peptide and Oligonucleotide CDMO Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Peptide and Oligonucleotide CDMO Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Peptide and Oligonucleotide CDMO Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Peptide and Oligonucleotide CDMO Sales Market Share by Country/Region (2025)
Figure 8. Peptide and Oligonucleotide CDMO Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type in 2025
Figure 10. Peptide and Oligonucleotide CDMO in Pharmaceutical and Biotechnology Companies
Figure 11. Global Peptide and Oligonucleotide CDMO Market: Pharmaceutical and Biotechnology Companies (2021-2026) & ($ millions)
Figure 12. Peptide and Oligonucleotide CDMO in Research Institutes
Figure 13. Global Peptide and Oligonucleotide CDMO Market: Research Institutes (2021-2026) & ($ millions)
Figure 14. Peptide and Oligonucleotide CDMO in Others
Figure 15. Global Peptide and Oligonucleotide CDMO Market: Others (2021-2026) & ($ millions)
Figure 16. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application in 2025
Figure 17. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Player in 2025
Figure 18. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Region (2021-2026)
Figure 19. Americas Peptide and Oligonucleotide CDMO Market Size 2021-2026 ($ millions)
Figure 20. APAC Peptide and Oligonucleotide CDMO Market Size 2021-2026 ($ millions)
Figure 21. Europe Peptide and Oligonucleotide CDMO Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size 2021-2026 ($ millions)
Figure 23. Americas Peptide and Oligonucleotide CDMO Value Market Share by Country in 2025
Figure 24. United States Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Region in 2025
Figure 29. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2021-2026)
Figure 30. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2021-2026)
Figure 31. China Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 35. India Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Country in 2025
Figure 38. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2021-2026)
Figure 39. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2021-2026)
Figure 40. Germany Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 41. France Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Peptide and Oligonucleotide CDMO Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 54. APAC Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 55. Europe Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 57. United States Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 58. Canada Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 59. Mexico Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 60. Brazil Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 61. China Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 62. Japan Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 63. Korea Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 65. India Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 66. Australia Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 67. Germany Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 68. France Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 69. UK Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 70. Italy Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 71. Russia Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 72. Egypt Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 73. South Africa Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 74. Israel Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 75. Turkey Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
Figure 76. Global Peptide and Oligonucleotide CDMO Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Peptide and Oligonucleotide CDMO Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Peptide and Oligonucleotide CDMO Market Size 2027-2032 ($ millions)
